Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.58% for the day ...
Stephen Tsang, MD, PhD, professor at Columbia University and attending physician at NewYork-Presbyterian Hospital, shared encouraging early findings on the use of optogenetic therapy for patients with ...
St. Jude researchers advance CASTs, enhancing precision and activity for next-generation genome-editing therapies.
Classical swine fever reduces productivity and harms animal welfare, but pigs have now been genetically edited to make them ...
The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...
Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...
2d
Reid Hoffman Warns Silicon Valley Blind Spot Could Fuel Next AI Revolution In Healthcare And Biology
LinkedIn co-founder Reid Hoffman warns that Silicon Valley's software obsession is limiting AI opportunities in healthcare ...
Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...
Zacks Investment Research on MSN
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
The invention has made it onto TIME’s 2025 Best Inventions list, in the food and drink category, and would be the first new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback